Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GM100 series
- Development stage
- Preclinical
- Lead developer
- GlycoMantra
- Modality
- Small Molecules
01
Overview
The GM100 series are galectin-3 antagonists developed by GlycoMantra, Inc. These compounds are being explored for various therapeutic indications, including **metastatic prostate carcinoma** and **triple negative breast cancer**. Galectin-3 is a protein involved in various biological processes, and inhibiting it may have therapeutic benefits in diseases like cancer and fibrosis.
- Other names
- Galectin-3 antagonistsGalectin3 antagonistsGalectin 3 antagonists
02
Targets
LGALS3 (Galectin-3)
Beyond the preview
Go deeper on GM100 series.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GM100 series.